

## Nuedexta—At a Glance

Generic Name	Dextromethorphan/quinidine sulfate
Manufacturer	Avanir Pharmaceuticals, Inc
Approval date	October 29, 2010
Approval indication	Pseudobulbar affect (PBA)
Available in pharmacies	Available now
Dosages available	20/10 mg capsule
Target dose	20/10 mg twice daily
Average cost	\$600/month
Likely marketing points	Only medication approved for PBA
Advantages over existing agents	No clear advantages over SSRIs; probably has fewer side effects than tricyclics

Source: TCPR, January 2012, Vol 10, Issue 1, Natural Treatments in Psychiatry